Freshfields advises SERB Pharmaceuticals on purchase of RSDL® (Reactive Skin Decontamination Lotion) Kit from Emergent BioSolutions Inc.

Freshfields advises Charterhouse portfolio company, SERB Pharmaceuticals on its acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. (NYSE: EBS). RSDL® is a medical device produced as a kit that removes or neutralizes chemical warfare agents from the skin. Freshfields advised on all aspects of this product carveout, including on supply chain related milestones and on all complex transitional and long-term services arrangements as well.

The Freshfields team was led by M&A partner Paul Humphreys and life sciences counsel Jeff Jay. The team included M&A senior associate Ted Haxby and associates Connor Smith and Patrick Boldea, as well as life sciences associates Dylan O’Connor, Jake Silvers and Laura Zhu. Employment and benefits advice was provided by partner Nicole Foster and associate Lina Zhu.  Antibribery and sanctions advice was provided by partner Stephanie Brown-Cripps and associate Seve Kale.  Restructuring advice was provided by partner Madlyn Primoff and associate Ellen Lawrence.